Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 21, 2024Clinics and PracticeOpen Access

A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

HUHiroshi UreshinoYTYusuke TakedaKKKazuharu Kamachi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ureshino et al. (2024) studied this question.

synapsesocial.com/papers/68e63d15b6db6435875cecafhttps://doi.org/10.3390/clinpract14040097
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study2024 · 10 citations
  2. 2Phylogenetic Perspectives in Innate Immunity1999 · 2,508 citations
  3. 3Neutrophil plasticity in the tumor microenvironment2019 · 836 citations
  4. 4Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study2017 · 157 citations
  5. 5Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease2013 · 417 citations